Argen-X (1AE) - Total Liabilities
Based on the latest financial reports, Argen-X (1AE) has total liabilities worth €1.36 Billion EUR (≈ $1.59 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Argen-X - Total Liabilities Trend (2016–2025)
This chart illustrates how Argen-X's total liabilities have evolved over time, based on quarterly financial data. See Argen-X working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Argen-X Competitors by Total Liabilities
The table below lists competitors of Argen-X ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yum! Brands Inc
NYSE:YUM
|
USA | $15.49 Billion |
|
Entergy Corporation
NYSE:ETR
|
USA | $52.87 Billion |
|
RWE Aktiengesellschaft
F:RWEA
|
Germany | €60.15 Billion |
|
State Street Corp
NYSE:STT
|
USA | $364.42 Billion |
|
Nanya Technology Corp
TW:2408
|
Taiwan | NT$49.08 Billion |
|
Interactive Brokers Group Inc
NASDAQ:IBKR
|
USA | $197.49 Billion |
|
Ferrovial S.A.
MC:FER
|
Spain | €19.75 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Argen-X's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1AE company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argen-X's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argen-X (2016–2025)
The table below shows the annual total liabilities of Argen-X from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.36 Billion ≈ $1.59 Billion |
+93.06% |
| 2024-12-31 | €704.24 Million ≈ $823.33 Million |
+58.27% |
| 2023-12-31 | €444.95 Million ≈ $520.19 Million |
+38.80% |
| 2022-12-31 | €320.56 Million ≈ $374.77 Million |
+1.43% |
| 2021-12-31 | €316.05 Million ≈ $369.50 Million |
-35.93% |
| 2020-12-31 | €493.32 Million ≈ $576.74 Million |
+28.94% |
| 2019-12-31 | €382.59 Million ≈ $447.29 Million |
+854.98% |
| 2018-12-31 | €40.06 Million ≈ $46.84 Million |
+54.22% |
| 2017-12-31 | €25.98 Million ≈ $30.37 Million |
-38.73% |
| 2016-12-31 | €42.40 Million ≈ $49.57 Million |
-- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more